Goldstein Nathan
Boston University School of Law, USA.
J Biolaw Bus. 2006;9(1):26-37.
The purpose of this paper is to examine the past, present and future of financial conflict of interest regulation in biomedical human subject testing. Part I will briefly review the forces giving rise to the current controversy. Part II will examine the more influential ethical codes on human subject testing and argue that they are inconclusive on the subject of financial conflicts of interest. Part III will examine the various regulations now in place and identify their serious flaws. Part IV will critique the leading proposals for reform. The Conclusion will synthesize the best features of the various proposals for reform and suggest improvements left unaddressed by these proposals.
本文旨在探讨生物医学人体试验中经济利益冲突监管的过去、现在和未来。第一部分将简要回顾引发当前争议的各种力量。第二部分将审视关于人体试验更具影响力的伦理准则,并论证它们在经济利益冲突问题上尚无定论。第三部分将考察现行的各种监管措施,并指出其严重缺陷。第四部分将对主要的改革提议进行批判。结论部分将综合各种改革提议的最佳特点,并提出这些提议未涉及的改进之处。